A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Rebamipide D4 | CAS 1219409-06-9 - Request Quote

Picture of Rebamipide D4

Rebamipide D4

SZ CAT No:SZ-R060D01
CAS No
1219409-06-9
Mol.F.
C19H11D4ClN2O4
Mol.Wt.
374.8
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Rebamipide D4 is chemically 2-(4-chlorobenzamido-2,3,5,6-d4-2,3,5,6-d4)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid. Rebamipide D4 is supplied with detailed characterization data compliant with regulatory guideline. Rebamipide D4 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Rebamipide.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

Buy 1219409-06-9

Purchase 1219409-06-9

Order 1219409-06-9

Enquire 1219409-06-9

price of 1219409-06-9

1219409-06-9 Supplier

1219409-06-9 Manufacturer

1219409-06-9 Exporter

buy high quality Rebamipide D4

Purchase Rebamipide D4

Rebamipide D4 suppliers

Rebamipide D4 manufacturers

Rebamipide D4 price

Order Rebamipide D4

Enquire Rebamipide D4

Rebamipide D4 cost

Rebamipide D4 Supplier

Rebamipide D4 Distributor

Rebamipide D4 for Method Validation

Rebamipide Reference Standard

Rebamipide D4 for ANDA Filing

Rebamipide D4 for Forced Degradation Studies

Rebamipide D4 Identification Standards

Rebamipide D4 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,